Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Cemiplimab + ISA101b |
Synonyms | |
Therapy Description |
ISA101b is an HPV16 vaccine comprised of a peptide string that includes the E6 and E7 HPV proteins and T cell epitopes, allowing for T-cell activation, and may result in antitumor activity (PMID: 27669306). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Cemiplimab | Libtayo | REGN2810|SAR439684 | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 | Libtayo (cemiplimab) is a human antibody that targets PD-1 (PDCD1) and prevents interaction with PD-L1 (CD274) and PD-L2 (PDCD1LG2), potentially resulting in increased anti-tumor immune response and decreased tumor growth (PMID: 28265006). Libtayo (cemiplimab) is FDA approved for use in patients with cutaneous squamous cell carcinoma, who are not not eligible for curative surgery or radiation, in patients with locally advanced or metastatic basal cell carcinoma who have received or are not eligible for a hedgehog pathway inhibitor, as first-line treatment in patients with advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression (TPS>=50%) and no EGFR, ALK, or ROS1 aberrations, and in combination with platinum-based chemotherapy as first-line treatment for patients with NSCLC without EGFR, ALK, or ROS1 alterations (FDA.gov). |
ISA101b | ISA-101b|ISA 101b | ISA101b is an HPV16 vaccine comprised of a peptide string that includes the E6 and E7 HPV proteins and T cell epitopes, allowing for T-cell activation, and may result in antitumor activity (PMID: 27669306). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04398524 | Phase II | Cemiplimab + ISA101b | A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC | Active, not recruiting | USA | ITA | ISR | GBR | FRA | ESP | DEU | CZE | BEL | 0 |
NCT04646005 | Phase II | Cemiplimab + ISA101b | Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy | Completed | USA | NLD | ITA | ESP | BRA | BEL | 2 |
NCT03669718 | Phase II | Cemiplimab + ISA101b Cemiplimab | A Randomized Phase 2 Study of Cemiplimab +/- ISA101b in HPV16-Positive OPC | Active, not recruiting | USA | POL | NLD | ITA | HUN | GBR | FRA | ESP | DEU | CZE | BRA | BEL | 1 |